Steris (STE) reported $1.28 billion in revenue for the quarter ended June 2024, representing a year-over-year decline of 0.4%. EPS of $2.03 for the same period compares to $2.00 a year ago. The reported revenue represents a surprise of +1.47% over the Zacks Consensus Estimate of $1.26 billion. With the consensus EPS estimate being $2.01, the EPS surprise was +1.00%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expecta ...

Steris (STE) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $2 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 1%. A quarter ago, it was expected that this medical products maker would post earnings of $2.41 per share when it actually produced earnings of $2.41, delivering no surprise. Over the last four quarters, the company has surpas ...

Core Insights - STERIS plc reported an 8% increase in total revenue from continuing operations for Q1 fiscal 2025, reaching $1.3 billion compared to $1.2 billion in Q1 fiscal 2024, with constant currency organic revenue growing by 6% [1][2] - The company reiterated its fiscal 2025 outlook, expecting revenue growth of 6.5-7.5% and adjusted earnings per diluted share in the range of $9.05 to $9.25 [7][8] Financial Performance - Net income for Q1 fiscal 2025 was $139.9 million or $1.41 per share, up from $130.6 million or $1.31 per diluted share in Q1 fiscal 2024 [2] - Adjusted net income for Q1 fiscal 2025 was $201.7 million or $2.03 per diluted share, compared to $182.5 million or $1.84 per diluted share in the same period last year [2] Segment Performance - Healthcare revenue grew by 10% to $901.2 million, driven by a 23% increase in consumable revenue and a 14% rise in service revenue, despite a 10% decline in capital equipment revenue [3] - Applied Sterilization Technologies (AST) revenue increased by 7% to $249.8 million, with service revenue growing by 7% and capital equipment revenue rising by 24% [4] - Life Sciences revenue decreased by 2% to $128.5 million, impacted by the divestiture of the CECS business, although consumable revenue grew by 13% [5] Cash Flow - Net cash provided by operations for Q1 fiscal 2025 was $303.7 million, an increase from $281.1 million in fiscal 2024 [6] - Free cash flow for Q1 fiscal 2025 was $195.7 million, down from $214.5 million in the prior year, primarily due to the timing of capital spending [6] Fiscal 2025 Outlook - The company expects constant currency organic revenue growth from continuing operations to be between 6-7% for fiscal 2025 [7] - Capital expenditures are anticipated to be approximately $360 million, with free cash flow expected to be around $700 million [8]

Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6% As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03 Fiscal 2025 outlook reiterated DUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1. ...

In its upcoming report, Steris (STE) is predicted by Wall Street analysts to post quarterly earnings of $2.03 per share, reflecting an increase of 1.5% compared to the same period last year. Revenues are forecasted to be $1.26 billion, representing a year-over-year decrease of 1.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe. Ahead of a c ...

DUBLIN, IRELAND, July 31, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. This represents a $0.05 increase in the dividend and the Company's 19th consecutive year of dividend growth. The dividend is payable on September 20, 2024, to shareholders of record at the close of business on September 5, 2024. Additional information about the U.S. tax treatment of dividends, including require ...

Core Points - STERIS plc announced a quarterly interim dividend of $0.57 per share, marking a $0.05 increase and the 19th consecutive year of dividend growth [1] - The dividend is scheduled to be paid on September 20, 2024, to shareholders of record as of September 5, 2024 [1] Company Overview - STERIS is a leading global provider of products and services that support patient care, with a focus on infection prevention [2] - The company aims to help customers create a healthier and safer world through innovative healthcare and life sciences products and services [2]

A press release detailing financial results will be issued after the U.S. market closes on August 6, 2024. DUBLIN, IRELAND, July 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 first quarter financial results at 9:00 a.m. ET on August 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, the ...

Company Overview - STERIS plc is a leading global provider of products and services that support patient care, with a focus on infection prevention [5] - The company aims to help customers create a healthier and safer world through innovative healthcare and life sciences products and services [5] Upcoming Financial Results - STERIS will host a conference call to discuss its fiscal 2025 first quarter financial results on August 7, 2024, at 9:00 a.m. ET [3] - A press release detailing the financial results will be issued after the U.S. market closes on August 6, 2024 [4] - For those unable to attend the live conference call, a replay will be available starting at 12:00 p.m. ET on August 7, 2024 [4] Investor Relations - Julie Winter is the Vice President of Investor Relations and Corporate Communications, and can be contacted for further information [6]

Earnings Surprise History STERIS plc (STE) is expected to release first-quarter fiscal 2025 results on Aug 6. Healthcare We assume the Healthcare backlog to have finally normalized during the fiscal first quarter, as the company might have been able to ship at a faster pace than the new orders. STERIS' focus on getting back to normal lead times must have helped it in meeting customer demand. Our model projects the segment's revenues to improve 7.1% from the year-ago reported figure. Within the segment, the ...